IMV Inc
TSX:IMV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
IMV Inc
Total Equity
IMV Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
IMV Inc
TSX:IMV
|
Total Equity
$21.5m
|
CAGR 3-Years
89%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Total Equity
CA$82m
|
CAGR 3-Years
62%
|
CAGR 5-Years
157%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Total Equity
$581.3m
|
CAGR 3-Years
13%
|
CAGR 5-Years
7%
|
CAGR 10-Years
40%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Total Equity
$581.8m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
28%
|
CAGR 10-Years
25%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Total Equity
CA$82m
|
CAGR 3-Years
85%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Total Equity
$167.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
IMV Inc
Glance View
IMV, Inc. is a clinical-stage biopharmaceutical company that engages in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company is headquartered in Dartmouth, Nova Scotia and currently employs 97 full-time employees. The company went IPO on 2007-10-24. The firm is using its DPX delivery technology to achieve targeted immune activation. The Company’s lead candidate, maveropepimut-S, is a T cell-activating immunotherapy that combines the platform with a cancer target: survivin. Its other candidates include DPX-RSV and DPX-COVID-19. Its DPX-RSV is a DPX-based vaccine candidate targeting the respiratory syncytial virus (RSV) strain A. The company is developing DPX-COVID-19, a vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using its DPX platform. The firm is also developing maveropepimut-S for the treatment of breast and ovarian cancer, as well as for Diffuse large B-cell lymphoma (DLBCL) and other malignancies.
See Also
What is IMV Inc's Total Equity?
Total Equity
21.5m
USD
Based on the financial report for Dec 31, 2021, IMV Inc's Total Equity amounts to 21.5m USD.
What is IMV Inc's Total Equity growth rate?
Total Equity CAGR 5Y
33%
Over the last year, the Total Equity growth was -30%. The average annual Total Equity growth rates for IMV Inc have been 89% over the past three years , 33% over the past five years .
